Glycomine, Inc.
Clinical trials sponsored by Glycomine, Inc., explained in plain language.
-
Promising new treatment for rare PMM2-CDG disease enters final testing
Disease control OngoingThis study tests a new drug called GLM101 for people with PMM2-CDG, a rare inherited condition that causes problems with movement, balance, and coordination. About 50 children and adults will receive weekly infusions of either GLM101 or a placebo for 24 weeks, followed by 24 week…
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
Promising treatment for rare genetic disease continues testing
Disease control ENROLLING_BY_INVITATIONThis study offers continued access to the experimental drug GLM101 for people with PMM2-CDG, a rare genetic disorder that affects movement and development. Participants who completed a previous GLM101 trial will receive weekly infusions to see how safe the drug is over the long t…
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Researchers track rare disease to unlock clues for future therapies
Knowledge-focused OngoingThis study is for people with PMM2-CDG, a rare genetic disorder. Researchers will collect medical information and test results from 120 participants over time. The goal is to learn more about how the disease progresses, which can help design better treatments in the future. No ex…
Sponsor: Glycomine, Inc. • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:18 UTC